Slides
Page 1
0000000000 SCHOTT PHARMA 9M 2026 Results Presentation Christian Mias , CEO | Reinhard Mayer , CFO The fiscal year 2026 runs from October 2025 to September 2026 . © SCHOTT Pharma
Page 2
This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations. This publication has been prepared by SCHOTT Pharma AG & Co. KGaA. It may contain statements which address such key issues as strategy, future financial results, events, competitive positions and product developments. Such forward-looking statements are subject to a number of risks, uncertainties and other factors, including, but not limited to those described in SCHOTT Pharma’s disclosures, in particular in the chapter “Risks” in SCHOTT Pharma’s annual report. Should one or more of these risks, uncertainties and other factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, perfor mances or achievements of SCHOTT Pharma may vary materially from those described in the relevant forward -looking statements. These statements may be identified by words such as “expect,” “want,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “est imate,” “will,” “project” or words of similar meaning. SCHOTT Pharma neither intends, nor assumes any obligation, to update or revise its forward -looking statements regularly in light of developments which differ from those anticipated. Stated competitive positions are based on management estimates supported by information provided by specialized external agen cies. Our financial reports, presentations, press releases and ad-hoc releases may include alternative financial metrics. These metrics are not defined in the IFRS (International Financial Reporting Standards). SCHOTT Pharma’s net assets, financial position and results of operations should not be assessed solely on the basis of these alternative financial metrics. Under no circumstances do they replace the performance indicators presented in the consolidated financial statements and calcula ted in accordance with the IFRS. The calculation of alternative financial metrics may vary from company to company despite the use of the same terminology. Further informatio n regarding the alternative financial metrics used at SCHOTT Pharma can be found on our web site (https://www.schott-pharma.com/investor-relations). The information contained in this presentation is provided as of the date of this presentation and is subject to change witho ut notice. Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals pro vided and percentages may not precisely reflect the absolute figures to which they refer. For technical reasons, there may be differences in formatting between the accounting records appearing in this document and t hose published pursuant to legal requirements. Disclaimer © SCHOTT Pharma2
Page 3
Business Update Christian Mias, CEO © SCHOTT Pharma 3
Page 4
EUR 282m Revenue (+8.3 % at constant currencies) EUR 75m EBITDA (margin of 26.8 %) 59% HVS revenue share Strong momentum in Q3 2026 © SCHOTT Pharma4
Page 5
39% 48% 55% 57% 57% 57% 60% FY 2022 FY 2023 FY 2024 9M 2025 FY 2025 9M 2026 Mid-term High level of HVS supports profitable growth © SCHOTT Pharma5 Expansion Innovation Trusted partner HVS drive growth and margin expansion. Strategy focuses on addressing pharma trends with innovation. Continuous increase of HVS revenue share reflects success. Share of revenue with HVS Value drivers Strategic importance of HVS
Page 6
© SCHOTT Pharma6 Partnering for customer success Trusted partner Agreement with key customer for glass syringes • Trusted partnership resulted in mutually beneficial agreement, reinforcing shared commitment to long-term value creation • Agreement includes revenue-related and future compensation components New role: Chief Commercial Officer (CCO) • Held by Fabian Stöcker, also Head of DCS; 14 years with SCHOTT in different leadership roles, thereof 10 years with SCHOTT Pharma • Aims to further enhance customer focus by aligning commercial activities across segments and departments Partnership with Nemera • Verified compatibility of Nemera´s pen injector platform with SCHOTT Pharma’s cartriQ® 3 ml ready-to-use cartridge • Collaboration supports safe and patient-centric therapies, addressing growing demand for homecare solutions
Page 7
Expansion Meeting growing demand with expansions Additional vial capacities in the U.S. • Significantly increased capacities for core and specialty vials, also in ready-to-use configuration • Strengthens SCHOTT Pharma´s position as a key partner in supporting critical healthcare infrastructure and rapid response ability in public health emergencies HVS Expansion in Hungary and Switzerland • Ramp-up of glass syringes in Hungary and sterile cartridges in Switzerland strengthen our HVS offering • Increases readiness for future demand in biologics and advanced drug delivery systems © SCHOTT Pharma7
Page 8
Financial Update Reinhard Mayer, CFO © SCHOTT Pharma8
Page 9
414 445 326 325 143 159 114 123 256 282 Revenue1 © SCHOTT Pharma9 Key developments Strong momentum in Q3 supported by both segments DCS delivered strong growth, driven by continued high demand for sterile cartridges and vials as well as specialty vials. Revenues in DDS picked up significantly in Q3 due to ongoing high demand for glass syringes for GLP-1 and increasing dynamics from non-mRNA in polymer. Strong sales growth in Q3 2026 EURm 1 Segment split excluding consolidation effects, cc = at constant currencies Q3 25 9M 25Q3 26 DCS DDS Growth at cc: +8.3% +4.4% +10.0% 9M 26 739 770 +4.1%
Page 10
100 110 114 96 38 38 42 36 7583 EBITDA1 and margin © SCHOTT Pharma10 Key developments Group EBITDA in 9M 2026 remained at a high level, while the EBITDA margin decreased year-on-year. DCS: EBITDA after 9M increased strongly, driven by volume growth and a favorable product mix. DDS: 9M EBITDA down due to lower polymer utilization, the impairment on customer-specific glass syringes, and additional costs in Q3 connected to infrastructure and process optimizations in production. EBITDA shaped by volume growth and extraordinary items EURm 1 Segment split excluding consolidation effects, cc = at constant currencies Q3 25 9M 25Q3 26 DCS DDS Margin: 26.8 % 26.7%32.3 % 28.9% -8.8% 9M 26 213 205-3.8%
Page 11
© SCHOTT Pharma11 Key developments EBIT decline of -10% due to EBITDA performance and a higher depreciation as a result of growth investments. Financial result improved because of lower interest expenses following optimized financing structure. Income taxes slightly down, representing an effective tax rate of 22.6%. Overall, net income decreased 9% yoy to EUR 103.4 and earnings per share (EPS) amounted to EUR 0.68. Further down the P&L… EURm 9M 2026 9M 2025 Δ yoy EBITDA 205.3 213.3 -3.8% Depreciation & Amortization -65.5 -57.3 +14.2% EBIT 139.7 156.0 -10.4% Financial result -6.2 -9.6 -35.6% EBT 133.6 146.4 -8.8% Income tax expense -30.2 -32.7 -7.8% Profit for the period 103.4 113.7 -9.0% EPS (EUR) 0.68 0.75 -9.3%
Page 12
Free cash flow © SCHOTT Pharma12 Key developments Free cashflow (FCF) surged 49% yoy benefiting from working capital changes, lower tax payments and an optimized financing structure. Cashflow from ongoing investing activities slightly below prior year’s level at EUR 82m. Delivering a significantly improved free cash flow EURm FCFOp. CF1 Inv. CF2 9M 2025 9M 2026 128 -88 40 141 -82 59 1 Op. CF = Cash flow from operating activities; 2 Inv. CF = Cash flow from ongoing investing activities Op. CF1 FCFInv. CF2
Page 13
© SCHOTT Pharma13 Increased FY 2026 guidance confirmed 1At constant currencies; 2Capex excluding leasing Additional information CAPEX2 of EUR 140 – 160m | HVS revenue share on prior year´s level Revenue growth1 5 - 6% EBITDA margin 27-28%
Page 14
Thank you for your attention. Upcoming Financial Events Feb 12, 2027 Q1 2027 results Dec 10, 2026 FY/Q4 2026 results Mar 3, 2027 AGM Upcoming Investor Events Sep 15-16, 2026 Morgan Stanley Healthcare Conference New York Sep 17, 2026 Royal Bank of Canda Roadshow Toronto Sep 21, 2026 Barclays MedTech Investor Trip Frankfurt Sep 22, 2026 Bank of America Global Healthcare Conference London © SCHOTT Pharma Investor Relations Corporate Communications Lea.Kaiser@schott.com Tobias.Erfurth@schott.com Jasko.Terzic@schott.com Katrin.Schreyer@schott.com